Elsevier

Annals of Oncology

Volume 32, Supplement 5, September 2021, Pages S685-S687
Annals of Oncology

661P Conditional survival and 5-year follow-up in CheckMate 214: First-line nivolumab + ipilimumab (N+I) versus sunitinib (S) in advanced renal cell carcinoma (aRCC)

https://doi.org/10.1016/j.annonc.2021.08.057Get rights and content
Under an Elsevier user license
open archive

Cited by (0)